Emerging therapeutics for primary peritoneal cancer

Brian Slomovitz, Michael J. Worley, Maurie Markman, Robert L. Coleman

Research output: Contribution to journalArticle

Abstract

Introduction: Primary peritoneal cancer describes a malignancy that originates from the peritoneal lining of the abdomen. The diagnosis is clearest when the ovaries are uninvolved; however, this is rarely the case and, as such, the declaration is often made pathologically by extrinsic or secondary involvement of the ovaries. The disease shares nearly all of the clinicopathologic features of primary ovarian cancer, most importantly, a molecular homology, which has made it unfruitful for considering it a different entity. Because of this, both standard of care treatment algorithms and contemporary drug development protocols nearly uniformly consider these cancers as primary ovarian cancers. Areas covered: A Medline search was performed as well as a review of trials presented in the National Cancer Institute clinical trials website (http://www.Clinicaltrials.gov). We also reviewed abstracts presented at recent oncology congresses, such as the 2010 Annual meetings of the Society of Gynecologic Oncologists and the American Society of Clinical Oncology. The purpose of this review is to highlight areas of current drug development for patients with primary peritoneal carcinoma. While there are numerous investigational agents being evaluated which follow patients with this disease, our review focuses on the most promising agents that are in mature clinical development. In addition, given the recent positive Phase III data of bevacizumab in the first-line setting for patients with this disease, we consider changes that we can anticipate in this field. Expert opinion: Numerous novel agents are being explored in this disease with the majority focusing on direct and indirect perturbations of tumor angiogenesis. Based on ongoing and recently completed investigations, targeted therapies are likely to become part of the armamentarium of first-line and recurrent treatment for patients with peritoneal cancers. Future studies of pathway-specific targeting will probably include pretreatment biomarker selection or eligibility criteria as well as combinatorial strategies.

Original languageEnglish (US)
Pages (from-to)71-84
Number of pages14
JournalExpert Opinion on Emerging Drugs
Volume16
Issue number1
DOIs
StatePublished - Mar 2011
Externally publishedYes

Fingerprint

Neoplasms
Ovarian Neoplasms
Ovary
Therapeutics
National Cancer Institute (U.S.)
Expert Testimony
Standard of Care
Pharmaceutical Preparations
Abdomen
Biomarkers
Clinical Trials
Carcinoma
Bevacizumab

Keywords

  • angiopoeitin inhibitors
  • anti-angiogenesis agents
  • bevacizumab
  • folate receptor antagonists
  • ovarian cancer
  • PARP inhibitors
  • primary peritoneal cancer
  • VEGF

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Emerging therapeutics for primary peritoneal cancer. / Slomovitz, Brian; Worley, Michael J.; Markman, Maurie; Coleman, Robert L.

In: Expert Opinion on Emerging Drugs, Vol. 16, No. 1, 03.2011, p. 71-84.

Research output: Contribution to journalArticle

Slomovitz, Brian ; Worley, Michael J. ; Markman, Maurie ; Coleman, Robert L. / Emerging therapeutics for primary peritoneal cancer. In: Expert Opinion on Emerging Drugs. 2011 ; Vol. 16, No. 1. pp. 71-84.
@article{0525e53e4c9647e289fbd6cbdc60253c,
title = "Emerging therapeutics for primary peritoneal cancer",
abstract = "Introduction: Primary peritoneal cancer describes a malignancy that originates from the peritoneal lining of the abdomen. The diagnosis is clearest when the ovaries are uninvolved; however, this is rarely the case and, as such, the declaration is often made pathologically by extrinsic or secondary involvement of the ovaries. The disease shares nearly all of the clinicopathologic features of primary ovarian cancer, most importantly, a molecular homology, which has made it unfruitful for considering it a different entity. Because of this, both standard of care treatment algorithms and contemporary drug development protocols nearly uniformly consider these cancers as primary ovarian cancers. Areas covered: A Medline search was performed as well as a review of trials presented in the National Cancer Institute clinical trials website (http://www.Clinicaltrials.gov). We also reviewed abstracts presented at recent oncology congresses, such as the 2010 Annual meetings of the Society of Gynecologic Oncologists and the American Society of Clinical Oncology. The purpose of this review is to highlight areas of current drug development for patients with primary peritoneal carcinoma. While there are numerous investigational agents being evaluated which follow patients with this disease, our review focuses on the most promising agents that are in mature clinical development. In addition, given the recent positive Phase III data of bevacizumab in the first-line setting for patients with this disease, we consider changes that we can anticipate in this field. Expert opinion: Numerous novel agents are being explored in this disease with the majority focusing on direct and indirect perturbations of tumor angiogenesis. Based on ongoing and recently completed investigations, targeted therapies are likely to become part of the armamentarium of first-line and recurrent treatment for patients with peritoneal cancers. Future studies of pathway-specific targeting will probably include pretreatment biomarker selection or eligibility criteria as well as combinatorial strategies.",
keywords = "angiopoeitin inhibitors, anti-angiogenesis agents, bevacizumab, folate receptor antagonists, ovarian cancer, PARP inhibitors, primary peritoneal cancer, VEGF",
author = "Brian Slomovitz and Worley, {Michael J.} and Maurie Markman and Coleman, {Robert L.}",
year = "2011",
month = "3",
doi = "10.1517/14728214.2011.526600",
language = "English (US)",
volume = "16",
pages = "71--84",
journal = "Expert Opinion on Emerging Drugs",
issn = "1472-8214",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Emerging therapeutics for primary peritoneal cancer

AU - Slomovitz, Brian

AU - Worley, Michael J.

AU - Markman, Maurie

AU - Coleman, Robert L.

PY - 2011/3

Y1 - 2011/3

N2 - Introduction: Primary peritoneal cancer describes a malignancy that originates from the peritoneal lining of the abdomen. The diagnosis is clearest when the ovaries are uninvolved; however, this is rarely the case and, as such, the declaration is often made pathologically by extrinsic or secondary involvement of the ovaries. The disease shares nearly all of the clinicopathologic features of primary ovarian cancer, most importantly, a molecular homology, which has made it unfruitful for considering it a different entity. Because of this, both standard of care treatment algorithms and contemporary drug development protocols nearly uniformly consider these cancers as primary ovarian cancers. Areas covered: A Medline search was performed as well as a review of trials presented in the National Cancer Institute clinical trials website (http://www.Clinicaltrials.gov). We also reviewed abstracts presented at recent oncology congresses, such as the 2010 Annual meetings of the Society of Gynecologic Oncologists and the American Society of Clinical Oncology. The purpose of this review is to highlight areas of current drug development for patients with primary peritoneal carcinoma. While there are numerous investigational agents being evaluated which follow patients with this disease, our review focuses on the most promising agents that are in mature clinical development. In addition, given the recent positive Phase III data of bevacizumab in the first-line setting for patients with this disease, we consider changes that we can anticipate in this field. Expert opinion: Numerous novel agents are being explored in this disease with the majority focusing on direct and indirect perturbations of tumor angiogenesis. Based on ongoing and recently completed investigations, targeted therapies are likely to become part of the armamentarium of first-line and recurrent treatment for patients with peritoneal cancers. Future studies of pathway-specific targeting will probably include pretreatment biomarker selection or eligibility criteria as well as combinatorial strategies.

AB - Introduction: Primary peritoneal cancer describes a malignancy that originates from the peritoneal lining of the abdomen. The diagnosis is clearest when the ovaries are uninvolved; however, this is rarely the case and, as such, the declaration is often made pathologically by extrinsic or secondary involvement of the ovaries. The disease shares nearly all of the clinicopathologic features of primary ovarian cancer, most importantly, a molecular homology, which has made it unfruitful for considering it a different entity. Because of this, both standard of care treatment algorithms and contemporary drug development protocols nearly uniformly consider these cancers as primary ovarian cancers. Areas covered: A Medline search was performed as well as a review of trials presented in the National Cancer Institute clinical trials website (http://www.Clinicaltrials.gov). We also reviewed abstracts presented at recent oncology congresses, such as the 2010 Annual meetings of the Society of Gynecologic Oncologists and the American Society of Clinical Oncology. The purpose of this review is to highlight areas of current drug development for patients with primary peritoneal carcinoma. While there are numerous investigational agents being evaluated which follow patients with this disease, our review focuses on the most promising agents that are in mature clinical development. In addition, given the recent positive Phase III data of bevacizumab in the first-line setting for patients with this disease, we consider changes that we can anticipate in this field. Expert opinion: Numerous novel agents are being explored in this disease with the majority focusing on direct and indirect perturbations of tumor angiogenesis. Based on ongoing and recently completed investigations, targeted therapies are likely to become part of the armamentarium of first-line and recurrent treatment for patients with peritoneal cancers. Future studies of pathway-specific targeting will probably include pretreatment biomarker selection or eligibility criteria as well as combinatorial strategies.

KW - angiopoeitin inhibitors

KW - anti-angiogenesis agents

KW - bevacizumab

KW - folate receptor antagonists

KW - ovarian cancer

KW - PARP inhibitors

KW - primary peritoneal cancer

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=79952123631&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952123631&partnerID=8YFLogxK

U2 - 10.1517/14728214.2011.526600

DO - 10.1517/14728214.2011.526600

M3 - Article

VL - 16

SP - 71

EP - 84

JO - Expert Opinion on Emerging Drugs

JF - Expert Opinion on Emerging Drugs

SN - 1472-8214

IS - 1

ER -